Breast Cancer (ATEMPT) 14-221

January 03, 2017

Sponsor: Memorial Sloan Kettering Cancer Center

Number: (ATEMPT) 14-221

This is a Phase II study of a drug called Trastuzumab, or Herceptin, which is designed to treat women with distinct form of early-stage breast cancer that produces a protein called HER2 that provides messages to cancer cells encouraging them to grow. This drug is meant to block the message to the cells; it also is meant to reduce or eliminate common side effects of chemotherapy such as hair loss and nausea.

Who’s eligible: Patients must have stage I HER2-positive breast cancer. Breast cancer surgery must have taken place 90 days or less before entering the study. At least five years must have passed since any prior chemotherapy. Patients may not have received prior paclitaxel therapy.

Patients must be physically well enough that they are fully ambulatory, capable of all self care, and are capable of all but physically strenuous activities. As an example, patients must be well enough that they would be able to carry out office work or light housework.

This study is for women age 18 and older.

Available at: Backus Hospital, The Hospital of Central Connecticut, Hartford Hospital.